
1. j biol chem. 2012 mar 23;287(13):9731-41. doi: 10.1074/jbc.m111.324319. epub 2012
jan 26.

cytochrome b mutation y268s conferring atovaquone resistance phenotype malaria
parasite results reduced parasite bc1 catalytic turnover protein
expression.

fisher n(1), abd majid r, antoine t, al-helal m, warman aj, johnson dj, lawrenson
as, ranson h, o'neill pm, ward sa, biagini ga.

author information: 
(1)liverpool school tropical medicine, pembroke place, liverpool l3 5qa,
united kingdom.

atovaquone anti-malarial drug used combination proguanil (e.g.
malarone(tm)) curative prophylactic treatment malaria. atovaquone,
a 2-hydroxynaphthoquinone, competitive inhibitor quinol oxidation
(q(o)) site mitochondrial cytochrome bc(1) complex. inhibition this
enzyme results collapse mitochondrial membrane potential,
disruption pyrimidine biosynthesis, subsequent parasite death. resistance 
to atovaquone field associated point mutations q(o) pocket 
of cytochrome b, notably near conserved
pro(260)-glu(261)-trp(262)-tyr(263) (pewy) region ef loop). effect 
this mutation extensively studied model organisms hitherto in
the parasite itself. here, performed molecular biochemical
characterization atovaquone-resistant field isolate, tm902cb. molecular
analysis strain reveals presence y268s mutation cytochrome 
b. y268s mutation shown confer 270-fold shift inhibitory
constant (k(i)) atovaquone concomitant reduction v(max) 
bc(1) complex âˆ¼40% 3-fold increase observed k(m) for
decylubiquinol. western blotting analyses reveal reduced iron-sulfur protein
content y268s bc(1) suggestive weakened interaction subunit 
and cytochrome b. gene expression analysis tm902cb strain reveals higher
levels expression, compared 3d7 (atovaquone-sensitive) control strain
in bc(1) cytochrome c oxidase genes. hypothesized observed
differential expression key genes offsets fitness cost
resulting reduced bc(1) activity.

doi: 10.1074/jbc.m111.324319 
pmcid: pmc3322985
pmid: 22282497  [indexed medline]

